The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Loss of smell
Documentation of laboratory-confirmed active SARS-CoV-2 infection, as determined by a nucleic acid (for example, reverse-transcriptase PCR) or antigen test from any respiratory tract specimen (for example, oropharyngeal, NP or nasal swab, or saliva) collected ≤72 hours (3 days) prior to randomization.
Participants are expected to begin study intervention ≤3 days from self-reported date of onset of any of the COVID-19-related symptoms from the following list:
Cough
Shortness of breath or difficulty breathing
Feeling feverish
Chills
Fatigue
Body pain or muscle pain or aches
Diarrhea
Nausea
Vomiting
Headache
Sore throat
Nasal obstruction or congestion
Nasal discharge
Loss of taste
One or more of the following signs/symptoms present within 24 hours prior to randomization:
Cough
Shortness of breath or difficulty breathing
Feeling feverish
Chills
Fatigue
Body pain or muscle pain or aches
Diarrhea
Nausea
Vomiting
Headache
Sore throat
Nasal obstruction or congestion
Nasal discharge
Participants at higher risk of progression to severe COVID-19 are defined as follows:
Age ≥65 years
Age ≥18 with 1 of the following:
Obesity (body mass index \[BMI\] ≥30 kilograms per square meter \[kg/m\^2\]). Note: BMI is rounded to the nearest whole number, for example 29.5 kg/m\^2 is rounded to 30 kg/m\^2.
Diabetes mellitus
Hypertension requiring daily prescribed therapy
Cardiovascular disease (requiring daily prescribed therapy or congenital heart disease)
Chronic lung disease (for example, chronic obstructive pulmonary disease, moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension) requiring daily prescribed therapy
Chronic kidney disease, defined as known current kidney impairment with a creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) \<60 milliliters (mL)/minute (min)/1.73 square meter (m\^2) within the past 12 months prior to randomization, as long as the participant does not have known CrCl \<30 mL/min by Cockcroft-Gault or require dialysis
Down syndrome
Sickle cell disease
One of the following immunocompromising conditions or immunosuppressive treatments:
Receiving chemotherapy or other therapies for cancer
Hematologic malignancy (active or in remission)
History of a hematopoietic stem cell or a solid organ transplant
Human immunodeficiency virus infection: not on antiretroviral therapy or with cluster of differentiation 4+ cell count \<200 cells per cubic millimeter
Combined primary immunodeficiency disorder
Taking immunosuppressive medications (for example, drugs to suppress rejection of transplanted organs or to treat rheumatologic and gastrointestinal conditions, such as anti-tumor necrosis factor agents, mycophenolate, and rituximab).
Note: Current use of some corticosteroids is exclusionary, due to concern for possible drug-drug interaction (DDI) with S-217622.

Criterios de exclusión

History of hospitalization for the current SARS-CoV-2 infection (that is, prior hospitalization for a prior episode of SARS-CoV-2 infection is allowable)
For the current SARS-CoV-2 infection, any positive SARS-CoV-2 molecular (nucleic acid) or antigen test from any respiratory tract specimen (for example, oropharyngeal, NP, or nasal swab, or saliva) collected ˃72 hours (3 days) prior to randomization. Participants with reinfection, defined as prior SARS-CoV-2 infection that began \>90 days prior to the current onset of symptoms with interval resolution of symptoms are eligible as long as the current infection has not been present for more than 3 days prior to randomization.
Current need for hospitalization or immediate medical attention in the opinion of the investigator
Current use of any medications prohibited with the study intervention. Individuals who have used Paxlovid or any other oral, inhaled, or injectable medication intended to treat the current SARS-CoV-2 infection before randomization are excluded. After randomization, locally available SARS-CoV-2 treatment (including but not limited to molnupiravir, mAbs, outpatient IV remdesivir, convalescent plasma, inhaled budesonide, favipiravir, and fluvoxamine) will be permitted, as long as there are no concerns for DDIs.
Note: Paxlovid use for a prior episode of COVID-19 is permitted.
Receipt of any investigational treatments for the current episode of SARS-CoV-2 at any time prior to randomization is exclusionary. Note: This does not include drugs approved for other uses and taken for those indications or COVID-19 vaccines. Note: Use of locally authorized or approved therapies to prevent COVID-19, such as mAbs given solely to prevent COVID-19, are not exclusionary.
Any co-morbidity requiring surgery within 7 days prior to randomization or that is considered life threatening in the opinion of the investigator within 28 days prior to randomization
Known allergy/sensitivity or any hypersensitivity to components of S-217622 or placebo for S-217622
Known (within 12 months prior to randomization) renal impairment defined as CrCl \<30 mL/min by Cockcroft-Gault or requiring dialysis
Known history of cirrhosis or liver decompensation (including ascites, variceal bleeding, or hepatic encephalopathy)
Participants who have used any of the following drugs within 14 days prior to randomization:
Strong cytochrome P453A inducer
Products containing St. John's Wort

Ubicaciones

CINME Centro Investigaciones Metabolicas, Pres. Jose Evaristo Uriburu 754, Piso 3 dpto 12

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Sanatorio De La Trinidad, Mitre Bartolome Mitre

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Hospital Italiano sede Central, Tte. Gral. Juan Domingo Perón 4190

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Centro Privado de Medicina Familiar, Mindout Research

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Centro De Investigaciones

Mar del Plata, Buenos Aires, Argentina

DIM Clínica Privada, Belgrano 136 - 5to piso

Ramos Mejía, Buenos Aires, Argentina

Hospital General Agudos Dr. J.M., Grl Justo José de Urquiza 609 2do piso, Pabellón Clínica Médica, Enf. Emergentes

Ramos Mejía, Buenos Aires, Argentina

Clínicas Zárate, F. Andrade 332

Zárate, Buenos Aires, Argentina

Sanatorio Privado ,Duarte Quiros

Quiros, Córdoba Province, Argentina

Instituto Médico de la, Fundación Estudios Clínicos, Italia 428, Rosario

Rosario, Sante Fe, Argentina

Clinica Mayo UMCB

San Miguel de Tucumán, Tucumán Province, Argentina

Clínica Olivos

Buenos Aires, Argentina

Sanatorio Allende, Av.

Córdoba, Argentina

CER San Juan,

San Juan, Argentina

Mendoza 2612, Rosario

Santa Fe, Argentina

A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19

Resumen

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

S-217622

Placebo

Ubicaciones

CINME Centro Investigaciones Metabolicas, Pres. Jose Evaristo Uriburu 754, Piso 3 dpto 12

Sanatorio De La Trinidad, Mitre Bartolome Mitre

Hospital Italiano sede Central, Tte. Gral. Juan Domingo Perón 4190

Centro Privado de Medicina Familiar, Mindout Research

Centro De Investigaciones

DIM Clínica Privada, Belgrano 136 - 5to piso

Hospital General Agudos Dr. J.M., Grl Justo José de Urquiza 609 2do piso, Pabellón Clínica Médica, Enf. Emergentes

Clínicas Zárate, F. Andrade 332

Sanatorio Privado ,Duarte Quiros

Instituto Médico de la, Fundación Estudios Clínicos, Italia 428, Rosario

Clinica Mayo UMCB

Clínica Olivos

Sanatorio Allende, Av.

CER San Juan,

Mendoza 2612, Rosario

Patrocinadores